ArticleCureus2025
Optimal Management of Bleeding and Thrombosis in Total Knee Arthroplasty: Tranexamic Acid With Acetylsalicylic Acid or Low-Molecular-Weight Heparin.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study compared the efficacy and safety of combining tranexamic acid, which reduces bleeding, with acetylsalicylic acid (ASA) or low-molecular-weight heparin (LMWH), which is used for venous thromboembolism (VTE) prophylaxis in patients undergoing total knee arthroplasty (TKA). Materials and methods A retrospective analysis was conducted on 86 patients who underwent primary unilateral TKA between 2014 and 2020. Patients were divided into Group 1 (intravenous tranexamic acid (TA) + acetylsalicylic acid) and Group 2 (intravenous tranexamic acid + low-molecular-weight heparin). Demographic data, perioperative blood loss, transfusion requirements, and complications were recorded and analyzed. Results Group 1 showed significantly lower total blood loss (TBL), drainage volume, and transfusion rates than Group 2. No significant differences were observed in hidden blood loss (HBL) or maximum hemoglobin drop between the groups. Postoperative complications, including VTE, wound issues, and systemic adverse events, were comparable between the two groups. The length of hospital stay was shorter in Group 1. Conclusion The combination of TA with ASA demonstrated superior outcomes in blood conservation and transfusion rates compared to TA with LMWH, with no increase in postoperative complications. These findings suggest that ASA is a safe and effective option for VTE prophylaxis in TKA patients when used with TA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.